Vaccinations for anal squamous cancer: Current and emerging therapies

John Berry, Sean C. Glasgow

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Human papillomavirus (HPV) infection is responsible for 4.3% of the global cancer burden. Since 2006, current HPV vaccines have reduced the prevalence of the virus in adolescent girls, reduced the prevalence of genital warts, and been proven to reduce the progression of anal intraepithelial neoplasia in men. Herein, we review the epidemiology, virology, and immunology behind the prophylactic HPV vaccines and current recommendations for its use. We also review future immune therapies being trialed for use against HPV-related cancers including anal cancer.

Anal cancer , human papillomavirus , anal intraepithelial neoplasia , anal squamous cell cancer.

Original languageEnglish
Pages (from-to)321-327
Number of pages7
JournalClinics in Colon and Rectal Surgery
Issue number6
StatePublished - 2018


Dive into the research topics of 'Vaccinations for anal squamous cancer: Current and emerging therapies'. Together they form a unique fingerprint.

Cite this